PARP1 and breast carcinoma: PARP inhibitors (PARPi) are the first clinically approved drugs designed to exploit synthetic lethality, which have been approved for adjuvant therapy in early stage BRCA-mutated breast cancer and salvage therapy in advanced BRCA-mutated breast cancer [42,43,44].